ADIL
Adial PharmaceuticalsADIL
ADIL
About: Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
Employees: 7
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
300% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 1
53% more capital invested
Capital invested by funds: $194K [Q3] → $296K (+$102K) [Q4]
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
27% more funds holding
Funds holding: 11 [Q3] → 14 (+3) [Q4]
1.49% more ownership
Funds ownership: 3.03% [Q3] → 4.53% (+1.49%) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for ADIL.
Financial journalist opinion
Based on 4 articles about ADIL published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Adial Pharmaceuticals Reports 2024 Fiscal Year Financial Results and Provides Business Update
GLEN ALLEN, Va., March 04, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2024 fiscal year ended December 31, 2024.
Neutral
GlobeNewsWire
2 weeks ago
Adial Pharmaceuticals Receives Positive Response from FDA Meeting Regarding Proposed In Vitro Bridging Strategy for AD04
FDA feedback confirms Adial's proposed in vitro bridging strategy to the Phase 3 formulation to fulfill the bridging requirement for the 505(b)(2) regulatory registration pathway for approval
Neutral
GlobeNewsWire
3 weeks ago
Adial Pharmaceuticals Granted New U.S. Patent Expanding Coverage of its Genetic-Based Approach to Treating and Diagnosing Alcohol Use Disorder and Other Drug Dependencies
New Patent covers claims which focus on method for identifying genetic markers in patients with alcohol or opioid related disorders
Neutral
GlobeNewsWire
4 weeks ago
Adial Pharmaceuticals Awarded New U.S. Patent Covering Genotype-Specific Treatment of Opioid-Related Disorders
New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence New Patent expands patent estate covering Adial's unique molecular genetic approach to diagnosing and potentially treating alcohol and drug dependence
Neutral
GlobeNewsWire
1 month ago
Adial Pharmaceuticals Announces Positive Clinical Study Results from the AD04-103 Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder
Completion enables the End-of-Phase 2 (EOP2) interaction with the FDA on the design of the Phase 3 program and is expected to facilitate ongoing partnership discussions
Neutral
GlobeNewsWire
3 months ago
Adial Pharmaceuticals Granted Key U.S. Patent for the Treatment of Alcohol and Drug Dependence Based on Expanded Genotype Combinations
GLEN ALLEN, Va., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced patent number 12150931 was issued on November 26, 2024 by the United States Patent and Trademark Office, expanding the Company's intellectual property coverage.
Positive
Zacks Investment Research
3 months ago
Adial Pharmaceuticals (ADIL) Upgraded to Buy: Here's What You Should Know
Adial Pharmaceuticals (ADIL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
4 months ago
Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer
GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024.
Neutral
MCAP MediaWire
4 months ago
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
Glen Allen, VA, October 23, 2024 – PRISM MediaWire – Adial Pharmaceuticals, Inc.
Neutral
GlobeNewsWire
4 months ago
Adial Pharmaceuticals to Present at the 2024 ThinkEquity Conference
GLEN ALLEN, Va., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced that it will be participating in The ThinkEquity Conference on October 30, 2024, at the Mandarin Oriental Hotel in New York.
Charts implemented using Lightweight Charts™